Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 6/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881342 | 0.89 | ELANE (0.41) | ELANEMAPTTP53L3MBTL1PDE5A | |
| SCHEMBL30745084 | 0.85 | PDE5A (0.48) | ELANEMAPTPDE5AADORA3KCNH2 | |
| SCHEMBL174888 | 0.85 | PDE5A (0.48) | ELANEMAPTPDE5AADORA3KCNH2 | |
| SCHEMBL2877930 | 0.82 | ELANE (0.41) | ELANEMAPTL3MBTL1PDE5A | |
| SCHEMBL2881224 | 0.81 | PDE5A (0.42) | ELANEMAPTL3MBTL1PDE5A | |
| SCHEMBL6068638 | 0.81 | MAPT (0.47) | ELANEMAPTL3MBTL1 | |
| SCHEMBL2882941 | 0.79 | ELANE (0.44) | ELANEMAPTL3MBTL1PDE5A | |
| SCHEMBL20140374 | 0.79 | L3MBTL1 (0.49) | ELANEMAPTTP53L3MBTL1 | |
| SCHEMBL20140434 | 0.79 | L3MBTL1 (0.46) | ELANEMAPTTP53L3MBTL1 | |
| SCHEMBL20140295 | 0.79 | ELANE (0.44) | ELANEMAPTL3MBTL1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113507-A1 | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113507-A1 | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113507-A1 | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2024361-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128454-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128454-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113507-A1 | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof | TNNI3, FABP3, PPIP5K2 | ELANE 3059/4885MAPT 3163/4885TP53 3733/4885 |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | ELANE 2397/4885MAPT 4591/4885TP53 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.